Fig. 4.

NF-кB activation is required for IL-1β-induced upregulation of miR-372 in hNSC. A: expression of miR-372 in IL-1β-treated hNSC was examined after mock treatment or treatment with the p38 MAPK inhibitor BIX 02188, the JNK inhibitor SP600125, or the IKK inhibitor TPCA-1, respectively. B and C: NF-кB (B) and miR-372 (C) were examined in IL-1β-treated hNSC, following siRNA knockdown of NF-кB. D and E: expression of KIF3B and NOSIP in IL-1β-treated hNSC was examined following treatment with small inhibitors (D) or NF-кB siRNAs (E). Data are means ± SD from at least 3 independent experiments. **P < 0.01 compared with mock or siRNA-NC; ns, not significant.